Astrazeneca Plc (AZN) 34.09 $AZN
AstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:16AM CDT
AstraZeneca (AZN) reported second-quarter 2016 core earnings of 83 cents per American Depositary Share, beating the Zacks Consensus Estimate of 42 cents.
INVA: 13.01 (+0.17), ANIP: 62.10 (+1.08), AZN: 34.09 (-0.12), NKTR: 17.53 (+0.35)
Look for Shares of AstraZeneca to Potentially Pullback after Yesterday's 7.26% Rise
Comtex SmarTrend(R) - Thu Jul 28, 11:57AM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.51 to a high of $33.95. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high of $31.57 on volume of 12.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
AstraZeneca Rises 7.26% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jul 28, 11:55AM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.51 to a high of $33.95. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high of $31.57 on volume of 12.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:49PM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) Biologic License Application (BLA) for brodalumab is up for review by an FDA panel.
VRX: 22.36 (+1.19), AZN: 34.09 (-0.12), AMGN: 173.43 (-0.72), BMY: 74.80 (-0.25)
TAGRISSO(R) (OSIMERTINIB) Met Primary Endpoint in Phase III 2nd-Line Lung Cancer Trial
BusinessWire - Mon Jul 18, 6:12AM CDT
--First randomized trial to evaluate the clinical benefit of an EGFR T790M medicine, and data are consistent with those supporting TAGRISSO approvals
AZN: 34.09 (-0.12)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 34.09 (-0.12), LLY: 82.72 (-0.60), GSK: 45.03 (-0.46), BMY: 74.80 (-0.25)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 22.36 (+1.19), UTHR: 124.86 (-0.99), AZN: 34.09 (-0.12)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 252.53 (+1.78), VRX: 22.36 (+1.19), AZN: 34.09 (-0.12), AMGN: 173.43 (-0.72)
AstraZeneca Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 23, 12:52PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.39% Gain
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 123.90 (-0.95), PFE: 35.29 (-1.10), AZN: 34.09 (-0.12), GSK: 45.03 (-0.46)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 80.09 (+0.52), PFE: 35.29 (-1.10), MRK: 57.65 (-0.68), AZN: 34.09 (-0.12)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.34% Loss
Comtex SmarTrend(R) - Tue Jun 14, 1:47PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 34.09 (-0.12)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 1.34% Sell Off
Comtex SmarTrend(R) - Tue Jun 14, 1:45PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 34.09 (-0.12)
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 34.09 (-0.12)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 34.09 (-0.12)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 252.53 (+1.78), IRWD: 14.24 (+0.41), AZN: 34.09 (-0.12), JNP: 7.29 (-0.13)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 22.36 (+1.19), AZN: 34.09 (-0.12), VRX.TO: 29.21 (+1.48)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 34.09 (-0.12)
AstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:16AM CDT
AstraZeneca (AZN) reported second-quarter 2016 core earnings of 83 cents per American Depositary Share, beating the Zacks Consensus Estimate of 42 cents.
INVA: 13.01 (+0.17), ANIP: 62.10 (+1.08), AZN: 34.09 (-0.12), NKTR: 17.53 (+0.35)
Look for Shares of AstraZeneca to Potentially Pullback after Yesterday's 7.26% Rise
Comtex SmarTrend(R) - Thu Jul 28, 11:57AM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.51 to a high of $33.95. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high of $31.57 on volume of 12.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
AstraZeneca Rises 7.26% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jul 28, 11:55AM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.51 to a high of $33.95. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high of $31.57 on volume of 12.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:49PM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) Biologic License Application (BLA) for brodalumab is up for review by an FDA panel.
VRX: 22.36 (+1.19), AZN: 34.09 (-0.12), AMGN: 173.43 (-0.72), BMY: 74.80 (-0.25)
TAGRISSO(R) (OSIMERTINIB) Met Primary Endpoint in Phase III 2nd-Line Lung Cancer Trial
BusinessWire - Mon Jul 18, 6:12AM CDT
--First randomized trial to evaluate the clinical benefit of an EGFR T790M medicine, and data are consistent with those supporting TAGRISSO approvals
AZN: 34.09 (-0.12)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 34.09 (-0.12), LLY: 82.72 (-0.60), GSK: 45.03 (-0.46), BMY: 74.80 (-0.25)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 22.36 (+1.19), UTHR: 124.86 (-0.99), AZN: 34.09 (-0.12)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 252.53 (+1.78), VRX: 22.36 (+1.19), AZN: 34.09 (-0.12), AMGN: 173.43 (-0.72)
AstraZeneca Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 23, 12:52PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.39% Gain
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 34.09 (-0.12)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 123.90 (-0.95), PFE: 35.29 (-1.10), AZN: 34.09 (-0.12), GSK: 45.03 (-0.46)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 80.09 (+0.52), PFE: 35.29 (-1.10), MRK: 57.65 (-0.68), AZN: 34.09 (-0.12)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.34% Loss
Comtex SmarTrend(R) - Tue Jun 14, 1:47PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 34.09 (-0.12)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 1.34% Sell Off
Comtex SmarTrend(R) - Tue Jun 14, 1:45PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 34.09 (-0.12)
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 34.09 (-0.12)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 34.09 (-0.12)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 252.53 (+1.78), IRWD: 14.24 (+0.41), AZN: 34.09 (-0.12), JNP: 7.29 (-0.13)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 22.36 (+1.19), AZN: 34.09 (-0.12), VRX.TO: 29.21 (+1.48)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 34.09 (-0.12)
